Nature’s Sunshine (Nasdaq: NATR), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025.
Q1 2025 Financial Summary vs. Same Year-Ago Quarter
Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).
GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.
Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million.
“2025 got off to a strong start, as first quarter revenue came in at $113 million, up 5% on a constant currency basis, and adjusted EBITDA came in at $11 million, up 20% versus prior year,”
said Terrence Moorehead, CEO of Nature’s Sunshine.
“We’re particularly pleased with the exceptional growth we’re seeing in Asia and Europe where markets like Taiwan, Japan and Central Europe continue to deliver strong double-digit growth. We’re also pleased to see early signs of stabilization in North America and continued improvements to gross margin. Despite the tremendous amount of uncertainty in the market, we remain confident in the underlying health of our business, and our performance reflects the power of our global growth strategies.